Back to search results

Minoxidil with Red-Light Therapy for Chemotherapy-Induced Hair Loss

This study is looking at ways to improve hair loss or thinning (alopecia) caused by chemotherapy in breast cancer patients. It compares using topical minoxidil alone to using minoxidil with a Revian RED LED-light cap. Minoxidil is a medication approved for hair loss that helps increase blood flow and stimulate hair growth. Low-level red-light therapy is a safe treatment that uses red light wavelengths to help with various skin conditions. The study aims to see if adding red-light therapy to minoxidil works better to improve hair density. Researchers will measure hair density after 6 months to see how well the treatments work. You may be able to join if you are an Ohio State University patient over 18 with breast cancer (stages I-IV) who has experienced significant hair loss from chemotherapy.

Study design
This interventional study plans to enroll 50 participants who will be randomly assigned to one of two treatment groups. It is not specified if the study is blinded.
What's involved
You would apply minoxidil to your scalp daily for 6 months. If in the red-light therapy group, you would also use the Revian RED LED-light cap for 10 minutes daily for 6 months.
Compensation
Not stated in the trial record.
Follow-up
After completing the 6-month treatment, participants will be followed up at 12 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07594678

Minoxidil With or Without Low-Level Red-Light Therapy for Improving Chemotherapy-Induced Alopecia in Breast Cancer Patients

Not Yet Recruiting
PHASE2Ages 18+InterventionalSupportive care
Ohio State University Comprehensive Cancer Center
~50 participants
Updated 2026-05-19 on ClinicalTrials.gov
What's tested:Electronic Health Record ReviewMinoxidilRevian RED LED-light capSurvey Administration

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Dean scale score
Measured over After 6 months of intervention

Conditions

Anatomic Stage I Breast Cancer AJCC v8
Anatomic Stage II Breast Cancer AJCC v8
Anatomic Stage III Breast Cancer AJCC v8
Anatomic Stage IV Breast Cancer AJCC v8
Chemotherapy-Induced Alopecia

Explore related trials

Breast CarcinomaChemotherapy-Induced Alopecia

Where it's being run

1 sites across 1 states
Ohio1

Study leadership

  • Brittany L Dulmage, MD · PRINCIPAL_INVESTIGATOR · Ohio State University Comprehensive Cancer Center

Who to contact

The Ohio State University Comprehensive Cancer Center
[email protected]
800-293-5066
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients will be Ohio State University patients \> 18 years old
Patients will have a diagnosis of breast cancer, stages I-IV
Patients will have been treated with a chemotherapy regimen containing either an anthracycline or taxane
Patients will have a loss of at least 50% of the hair on the scalp by the final chemotherapy infusion
Patients will NOT be pregnant or nursing women
Patients will NOT have a history of scarring/cicatricial alopecia or alopecia areata
Patients will NOT have a known sensitivity to minoxidil
Patients will NOT have ongoing treatment with an antibody-drug conjugate or immunotherapy

What this trial measures

  • Dean scale scoreAfter 6 months of intervention

    The Dean scale measures hair loss along a 4-grade scale. Grade 1 = \<25% hair loss. Grade 2= 25-50% hair loss. Grade 3=50-75% hair loss. Grade 4 = \>75% hair loss. Success will be defined as Dean scale score of 1 or 0. This will be based on clinical photographs taken at the initial and 6-month visits and scored by two board-certified dermatologists. Will construct two-sided 95% confidence intervals for improvement from baseline and differences between randomized groups, including the proportion of patients with a Dean score of 1 or 0 at 6 months.